



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/505,407

08/23/2004

Vladimir Bykov

1505-1052

8979

466 7590 04/03/2009

YOUNG & THOMPSON
209 Madison Street
Suite 500
ALEXANDRIA, VA 22314

EXAMINER

VAKILI, ZOHREH

ART UNIT

PAPER NUMBER

1614

MAIL DATE

DELIVERY MODE

04/03/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/505,407	Applicant(s) BYKOV ET AL.	
	Examiner ZOHREH VAKILI	Art Unit 1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 February 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 16 and 18 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 16 and 18 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claims 16 and 18 are presented for examination.

Applicant's Amendment filed February 12, 2009 has been received and entered into the present application. Claims 16 and 18 are pending and are herein examined on the merits.

Applicant's arguments, filed February 12, 2009 have been fully considered. Rejections not reiterated from previous Office Actions are hereby withdrawn. The following rejections are either reiterated or newly applied. They constitute the complete set of rejections presently being applied to the instant application.

Claim Rejections - 35 USC § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 16 and 18 are rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. This is an Enablement rejection.

The specification does not reasonably provide enablement for “treating all mutant p53 mediated cancer and further “treating other types of cancer in a mammalian subject” as broadly claimed in claim 16. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

To be enabling, the specification of the patent application must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557, 1561 (Fed. Cir. 1993). Explaining what is meant by “undue experimentation,” the Federal Circuit has stated that:

The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention. *PPG v. Guardian*, 75 F.3d 1558, 1564 (Fed. Cir. 1996).

Attention is directed to In re Wands, 8 USPQ2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factors to consider when assessing if a disclosure would have required undue experimentation. Citing Ex parte Forman, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors:

Art Unit: 1614

- 1) the quantity of experimentation necessary,
- 2) the amount of direction or guidance provided,
- 3) the presence or absence of working examples,
- 4) the nature of the invention,
- 5) the state of the prior art,
- 6) the relative skill of those in the art,
- 7) the predictability of the art, and
- 8) the breadth of the claims.

Each factor is addressed below on the basis of comparison of the disclosure, the claims and the state of the art in the assessment of undue experimentation.

- 1) the nature of the invention; state of the prior art; relative skill of those in the art; and the predictability of the art;

The invention is directed to a method for treating mutant p53 mediated diseases such as cancer in a mammal. The claimed invention relates to treating a mammalian subject, which encompasses both any animal and any disease. Various diseases having various different causes are not treatable by a single composition. Given the great diversity between various diseases (viral infections, bacterial infection, cancers, autoimmune diseases, clogged arteries, neurological diseases, etc.), the unpredictability of treating an animal (e.g., no specific disease) has a number of facets, as discussed hereinafter.

A. Treatment of Disease Type

While the state of the art is relatively high with regard to the treatment of specific diseases with a specific agent, it is long underdeveloped with regard to the treatment of an animal broadly, that is, general treatment, with no specific disease combined with a specific drug therefore. In particular, there is no known "treatment" drug, that can treat,

Art Unit: 1614

“all that ails you”. This is why the National Cancer Institute (NCI) has the extensive *in vitro* drug-screening program it does. As discussed by the court in In re Brana, 51 F.3d 1560 (Fed. Cir. 1995), *in vitro* assays are used by NCI (such as the P388 and L1210 lymphocytic leukemia tests at issue therein) to measure the potential antitumor properties of a candidate compound. Brana at 1562-63. If success is shown in this initial screening step, this demonstrates that at least one cancer type (e.g., lymphocytic leukemia) is sensitive thereto, and provides the incentive to select it for further studies to determine its usefulness as a chemotherapeutic agent against other cancer types (lung, breast, colon, etc.) Id. at 1567-68. These *in vitro* tests are considered reasonably correlative of success *in vivo*.

Thus, a considerable amount of *in vitro* empirical testing is required, with no *a priori* expectation of success being present, before a candidate for even treating a specific disease, such as, breast cancer.

B. The therapeutic agent used

The therapeutic agent has no correlation treating which diseases. Thus, it is unclear, which type of cancer this drug is going to treat.

2) the breadth of the claims; the scope of the method claims include a method for treating cancer in a mammal. The claims are very broad and inclusive of “treating a mammalian subject” generally, which includes any treatment. Also, the claims are so broad that they do not correlate which drug treat which ailments.

3) the predictability or unpredictability of the art; the art does not enable a person of ordinary skill in the art to make and use the claimed invention without resorting to undue

Art Unit: 1614

experimentation. The burden of enabling one skilled in the art to a method for treating all types of cancer in a mammal would be much greater than that enabling the treatment. In the instant case, the specification does not provide guidance as to how one skilled in the art would accomplish the objective of treating other types of cancer. Nor is there any guidance provided as to a specific protocol to be utilized in order to show the efficacy of the presently claimed active ingredients for treating other types of cancer.

No experimental evidence or mechanism of action for supporting treating all types of cancer using the specified actives by simply administering, by any method, an amount of the claim specified active agents. The specification fails to enable one of ordinary skill in the art to practice the presently claimed method for treating the risk of all types of tumors.

It is unpredictable to practice with a mammalian subject treating for all types of cancer with a chemical administration as instantly claimed. The specification is viewed as lacking an adequate enablement of where all types of cancer may be actually treated.

- 4) the relative skill of those in the art; the relative skill of those in the art of pharmaceuticals is high.
- 5) the amount of direction or guidance presented; the specification and the example does not provide any guidance in terms of treating other types of cancer. The specification provides no direction for ascertaining, *a priori*, which diseases can be treated with which drug.

Art Unit: 1614

6) the presence or absence of working examples; no working examples are provided for treating all types of cancer with the same compound, for example in a patient, in the specification. The applicant has not provided any competent evidence or disclosed any tests that are highly predictive for the preventative effects of the instant composition. Note that in cases involving physiological activity such as the instant case, “the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved”. See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).

7) the quantity of experimentation necessary; the quantity of experimentation would be an undue burden to one of ordinary skill in the art and amount to the trial and error type of experimentation. Thus, factors such as “sufficient working examples”, “the level of skill in the art” and “predictability”, etc. have been demonstrated to be sufficiently lacking in the instant case for the instant process claims. In view of the breadth of the claims, the chemical nature of the invention and unpredictability of treating all types of cancer in a mammal, and the lack of working examples regarding the activity as claimed, one skilled in the art would have to undergo an undue amount of experimentation to use the instantly claimed invention commensurate in scope with the claims. The lack of adequate guidance from the specification or prior art with regard to the actual treatment fails to rebut the presumption of unpredictability present in this art. Applicants fail to provide the guidance and information required to ascertain which particular disease the claimed agent will be effective against without resorting to undue experimentation. Applicant's limited disclosure of the treatment of is not sufficient to

Art Unit: 1614

justify claiming all treatment broadly.

In consideration of each of factors 1-7, it is apparent that there is undue experimentation because of variability in prediction of outcome that is not addressed by the present application disclosure, examples, teaching and guidance presented. Absent factual data to the contrary, the amount and level of experimentation needed is undue.

Response to Arguments

Applicant has amended the claims to indicate that the method is for treating a mutant p53 mediated cancer. By amending the claim Applicant has not overcome the rejection. Whether it is a mutant p53 mediated cancer or a mutant p53 mediated disease such as cancer Applicant has not shown that one compound or one medication can treat all kinds of mutant p53 mediated cancers or diseases such as cancer. Applicant's remarks have been fully and carefully considered in their entirety, but fail to be persuasive.

Applicant's amendments and remarks have been carefully considered in their entirety, but fail to be persuasive in establishing error in the propriety of the present rejection.

For these reasons, and those already made of record at pages 2-8 of the previous Office Action dated February 12, 2009 rejection of claims 16 and 18 remain proper and is **maintained**.

Conclusion

No claims of the present application are allowed.

THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh Vakili whose telephone number is 571-272-3099. The examiner can normally be reached on 8:30-5:00 Mon.-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Zohreh Vakili

Patent Examiner 1614

March 17, 2009

/Ardin Marschel/

Supervisory Patent Examiner, Art Unit 1614